"The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemi"...
There is no specific treatment for overdose with FENOGLIDE. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.
FENOGLIDE is contraindicated in:
- patients with severe renal dysfunction, including those receiving dialysis [see CLINICAL PHARMACOLOGY]
- patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see WARNINGS AND PRECAUTIONS]
- patients with pre-existing gallbladder disease [see WARNINGS AND PRECAUTIONS]
- nursing mothers [see Use In Specific Populations]
- patients with a known hypersensitivity to fenofibrate [see WARNINGS AND PRECAUTIONS]
Last reviewed on RxList: 4/14/2016
Additional Fenoglide Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Tips to keep it under control.